REVIVA PHARMACEUTICALS HOLDINGS, INC.(RVPH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RVPH Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH), a Healthcare sector company. RVPH is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RVPH by reported 13-F value include MILLENNIUM MANAGEMENT, HIGHBRIDGE CAPITAL MANAGEMENT, ARMISTICE CAPITAL, based on the most recent SEC filings. RVPH trades on the Nasdaq exchange and files with the SEC under CIK 1742927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REVIVA PHARMACEUTICALS HOLDINGS, INC. directly from SEC EDGAR.
Net Income
Q2 2026
$-2.4M
ROIC
Q2 2026
-68.2%
D/E Ratio
Q2 2026
0.01
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+33.6% YoYOperating Income
+34.4% YoYTotal Assets
+2.7% YoYTotal Debt
-11.2% YoYOp. Cash Flow
+26.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-19.9M +33.6% | $-29.9M +23.8% | $-39.3M -38.9% | $-28.3M -231.6% | $-8.5M -125.2% | $-3.8M |
| Operating Income | $-20.2M +34.4% | $-30.8M +22.0% | $-39.5M -39.9% | $-28.2M -179.4% | $-10.1M -315.0% | $-2.4M |
| Total Assets | $15.9M +2.7% | $15.5M -34.6% | $23.7M +25.2% | $18.9M -39.7% | $31.4M +258.4% | $8.8M |
| Total Debt | $406.9K -11.2% | $458.2K | $0.00 | $0.00 | — | — |
| Operating Cash Flow | $-24.6M +26.7% | $-33.5M -18.4% | $-28.3M -49.4% | $-19.0M -77.7% | $-10.7M -186.3% | $-3.7M |
Get alerted when RVPH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for REVIVA PHARMACEUTICALS HOLDINGS, INC. including:
Top Institutional Holders of RVPH
MILLENNIUM MANAGEMENT LLC
$579.3K793,948 shHIGHBRIDGE CAPITAL MANAGEMENT LLC
$556.2K762,236 shARMISTICE CAPITAL, LLC
$432.0K592,079 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$366.7K502,300 shGSA CAPITAL PARTNERS LLP
$191.0K261,898 shVANGUARD CAPITAL MANAGEMENT LLC
$85.8K117,568 shWarberg Asset Management LLC
$66.2K90,772 shGEODE CAPITAL MANAGEMENT, LLC
$53.3K72,992 shRENAISSANCE TECHNOLOGIES LLC
$31.4K43,002 shVirtu Financial LLC
$24.0K32,905 sh
| Fund | Value | Shares |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | $579.3K | 793,948 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $556.2K | 762,236 |
| ARMISTICE CAPITAL, LLC | $432.0K | 592,079 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $366.7K | 502,300 |
| GSA CAPITAL PARTNERS LLP | $191.0K | 261,898 |
| VANGUARD CAPITAL MANAGEMENT LLC | $85.8K | 117,568 |
| Warberg Asset Management LLC | $66.2K | 90,772 |
| GEODE CAPITAL MANAGEMENT, LLC | $53.3K | 72,992 |
| RENAISSANCE TECHNOLOGIES LLC | $31.4K | 43,002 |
| Virtu Financial LLC | $24.0K | 32,905 |
More Healthcare Companies
View all Healthcare →Put RVPH on your watchlist
Track score changes the day REVIVA PHARMACEUTICALS HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RVPH a good stock to buy?
13F Pro's AI-powered analysis of REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RVPH are available on the RVPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RVPH is classified as a small company.
Which hedge funds own RVPH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RVPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REVIVA PHARMACEUTICALS HOLDINGS, INC.'s investment landscape.